{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:01:55Z","timestamp":1779310915032,"version":"3.51.4"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"928","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The antiphospholipid syndrome (APS, Hughes\u2019 syndrome), first described in 1983, is a prothrombotic disease in which neurological events feature prominently. Strokes, transient ischaemic attacks, and headaches (including migraine) are important complications. However, it is clear that other neurological symptoms, including diplopia, memory loss, ataxia, and \u201cmultiple sclerosis-like\u201d features are common. A notable feature of Hughes\u2019 syndrome is the clinical response to anticoagulants; features such as headache and memory loss often improving dramatically with appropriate warfarin dosage. APS may well become recognised as an important (and potentially treatable) cause of neurological disease.<\/jats:p>","DOI":"10.1136\/pmj.79.928.81","type":"journal-article","created":{"date-parts":[[2003,3,5]],"date-time":"2003-03-05T16:04:10Z","timestamp":1046880250000},"page":"81-83","source":"Crossref","is-referenced-by-count":115,"title":["Migraine, memory loss, and \u201cmultiple sclerosis \u201d. Neurological features of the antiphospholipid (Hughes\u2019) syndrome"],"prefix":"10.1093","volume":"79","author":[{"given":"G R V","family":"Hughes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2003,2,1]]},"reference":[{"key":"2023042409330711100_R1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4471-3666-8_5","article-title":"Cerebral disease in the antiphospholipid syndrome","volume-title":"Hughes syndrome: antiphospholipid syndrome","author":"Narvarreta","year":"2000"},{"key":"2023042409330711100_R2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/bmj.287.6399.1088","article-title":"Thrombosis, abortion, cerebral disease and the lupus anticoagulant.","volume":"287","author":"Hughes","year":"1983","journal-title":"BMJ"},{"key":"2023042409330711100_R3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4471-3666-8_1","article-title":"Hughes syndrome: history","volume-title":"Hughes syndrome: antiphospholipid syndrome","author":"Khamasha","year":"2000"},{"key":"2023042409330711100_R4","first-page":"47","article-title":"Cerebral infarction in systeic lupus. Association with anticardiolipin antibodies.","volume":"2","author":"Harris","year":"1984","journal-title":"Clin Exp Rheumatol"},{"key":"2023042409330711100_R5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1191\/096120301678646119","article-title":"Sticky blood and headache.","volume":"10","author":"Cuadrado","year":"2001","journal-title":"Lupus"},{"key":"2023042409330711100_R6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/qjmed\/93.5.317","article-title":"Migraine and stroke in young women.","volume":"93","author":"Cuadrado","year":"2002","journal-title":"Q J Med"},{"key":"2023042409330711100_R7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-4471-3666-8_11","article-title":"Off the beaten track: a clinician\u2019s view","volume-title":"Hughes syndrome: the antiphospholipid syndrome","author":"Hughes","year":"2000"},{"key":"2023042409330711100_R8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/jnnp.48.2.185","article-title":"Epilepsy: an early symptom of SLE.","volume":"48","author":"Mackworth-Young","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023042409330711100_R9","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0002-9343(00)00617-3","article-title":"Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders.","volume":"109","author":"Peltola","year":"2000","journal-title":"Am J Med"},{"key":"2023042409330711100_R10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/978-1-4471-3666-8_38","article-title":"The contribution of experimental models to our understanding of etiology, pathogenesis and novel therapies in the antiphospholipid syndrome","volume-title":"Hughes syndrome: antiphospholipid syndrome","author":"Blank","year":"2000"},{"key":"2023042409330711100_R11","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00005792-200001000-00006","article-title":"Can Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature.","volume":"79","author":"Cuadrado","year":"2002","journal-title":"Medicine"},{"key":"2023042409330711100_R12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1191\/096120398678919624","article-title":"Outcome of patients with anticardiolipin antibodies: a ten year follow-up of 52 patients.","volume":"7","author":"Shah","year":"1998","journal-title":"Lupus"},{"key":"2023042409330711100_R13","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJM199504133321504","article-title":"The management of thrombosis in the antiphospholipid antibody syndrome.","volume":"332","author":"Khamashta","year":"1995","journal-title":"N Engl J Med"},{"key":"2023042409330711100_R14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/qjmed\/94.2.114","article-title":"Migraine in Hughes syndrome\u2014heparin as a therapeutic trial.","volume":"94","author":"Cuadrado","year":"2001","journal-title":"Q J Med"},{"key":"2023042409330711100_R15","first-page":"2637","article-title":"The value of IgA antiphospholipid testing for the diagnosis of antiphospholipid (Hughes) syndrome in SLE.","volume":"28","author":"Bertolaccini","year":"2001","journal-title":"J Rheumatol"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/79\/928\/81\/50038661\/postgradmedj-79-81.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/79\/928\/81\/50038661\/postgradmedj-79-81.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T09:52:06Z","timestamp":1682329926000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/79\/928\/81\/7045590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,1]]},"references-count":15,"journal-issue":{"issue":"928","published-online":{"date-parts":[[2003,2,1]]},"published-print":{"date-parts":[[2003,2,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pmj.79.928.81","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2003,2]]},"published":{"date-parts":[[2003,2,1]]}}}